Curza Inc.

Curza Inc. is a for-profit biotechnology company registered in the System for Award Management (SAM.gov) since October 2014, specializing in pharmaceutical research and development with a focused strategy on antibiotic innovation. The company is actively engaged in developing novel broad-spectrum antibiotics targeting multidrug-resistant bacterial infections, particularly concentrating on Gram-negative pathogens that pose significant challenges in clinical treatment settings. Curza's core research strategy involves developing innovative antibiotic compounds that can selectively inhibit bacterial protein synthesis while minimizing potential cytotoxic effects on mammalian cells, representing a cutting-edge approach to addressing antimicrobial resistance.

Through multiple federal grant awards from the National Institute of Allergy and Infectious Diseases (NIAID), Curza has been advancing its CZ-02 antibiotic development platform, receiving project grants totaling approximately $2 million between 2020 and 2024. These grants, all part of the Allergy and Infectious Diseases Research program (CFDA 93.855), support the company's research into developing a new class of antibiotics specifically designed to combat multidrug-resistant Gram-negative bacterial infections. The grants have funded critical research aims including optimizing oral bioavailability, conducting in vivo pharmacokinetic studies, performing efficacy evaluations in animal models, and developing lead compounds targeting pathogens like Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, and Escherichia coli. Each successive grant has progressively advanced Curza's research, with the most recent awards focusing on preparing a lead antibiotic candidate for potential IND-enabling studies and eventual clinical development.